This title appears in the Scientific Report :
2018
Please use the identifier:
http://hdl.handle.net/2128/17406 in citations.
Please use the identifier: http://dx.doi.org/10.4236/wjns.2018.81006 in citations.
Activated Microglia in the Brain: Mitochondrial and Cell Membrane-Associated Targets for Positron Emission Tomography
Activated Microglia in the Brain: Mitochondrial and Cell Membrane-Associated Targets for Positron Emission Tomography
The emission tomographic imaging of activated microglia in the brain moves into the focus of neuroscientific research with increasing recognition of contributions of early inflammatory processes to neurodegenerative, traumatic, cancerous and infectious diseases of the brain. Whereas the mitochondria...
Saved in:
Personal Name(s): | Pissarek, Margit (Corresponding author) |
---|---|
Contributing Institute: |
Nuklearchemie; INM-5 |
Published in: | World Journal of Neuroscience, 08 (2018) 01, S. 50 - 81 |
Imprint: |
Irvine, CA
Scientific Research Publ.
2018
|
DOI: |
10.4236/wjns.2018.81006 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging |
Subject (ZB): | |
Link: |
OpenAccess OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.4236/wjns.2018.81006 in citations.
The emission tomographic imaging of activated microglia in the brain moves into the focus of neuroscientific research with increasing recognition of contributions of early inflammatory processes to neurodegenerative, traumatic, cancerous and infectious diseases of the brain. Whereas the mitochondrial isoform of the 18 kDa translocator protein (TSPO1) has been the main cellular target for positron emission tomography (PET) of this type of cells for decades, alternative marker proteins in the plasma membrane of microglia challenge efforts in ligand development, recently. The present report includes PET approaches using the chemokine receptor CX3CR1 and the FR2 folate receptor in parallel to small molecule PET tracers available for in vivo visualization of the “classical” target TSPO1. It compares first and second generation of TSPO1 ligands as well as new compounds like the tetrahydrocarbazole [18F]GE-180 and the quinazoline [11C]ER176 presumed to reduce polymorphism-related inter-subject variations, with allosteric ligands for the chemokine receptor CX3CR1 and with radio labelled folate conjugates targeting the folate “cargo” receptor FR1 and the FR2 receptor characteristic for anti-inflammatory M2 microglia. |